Previous Close | 1.3500 |
Open | 1.3500 |
Bid | 1.3000 x 0 |
Ask | 1.3100 x 0 |
Day's Range | 1.3000 - 1.3500 |
52 Week Range | 1.1100 - 6.2200 |
Volume | |
Avg. Volume | 2,248,766 |
Market Cap | 424.876M |
Beta (5Y Monthly) | 3.02 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -6.1050 |
Earnings Date | Feb 09, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 1.92 |
First off, a massive valuation gap must exist between a company's current share price and its fair value estimate. Under normal circumstances, the market is fairly efficient at pricing equities, but sizable valuation gaps can form when Wall Street has serious doubts about a company's business model. Second, and perhaps most importantly, the company must be able to build a solid competitive moat to protect profits over the long-term.
Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today that it has scheduled a conference call to discuss the results for its second quarter fiscal year 2023 on Thursday, February 9, 2023 at 5:00 p.m. Eastern Time | 3:00 p.m. Mountain Time. The Company will report its financial results for the second quarter fiscal year 2023 after the close of markets that same day.
With discretionary spending under pressure, investors are shying away from this Canadian cannabis stock today.